Hologic (HOLX) Releases Earnings Results, Beats Expectations By $0.01 EPS

Hologic (HOLX) reported quarterly earnings results on Wednesday, Apr-27-2016. The company said it had a profit of $0.47 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $0.46. The company posted revenue of $693.30 million in the period, compared to analysts expectations of $687.43 million. The company’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 EPS.

Hologic closed down -0.06 points or -0.16% at $37.44 with 33,78,011 shares getting traded on Friday. Post opening the session at $37.5, the shares hit an intraday low of $37.29 and an intraday high of $37.7 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Feb 26, 2016, David R Jr Lavance (director) sold 11,621 shares at $34.50 per share price. According to the SEC, on Nov 12, 2015, Lawrence M Levy (director) sold 20,000 shares at $40.35 per share price. On Sep 9, 2015, Wayne Wilson (director) sold 100,000 shares at $39.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.


Leave a Reply

Hologic - Is it time to Sell?

Top Brokerage Firms are advising their investors on Hologic. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.